A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. - Wikidata - awgldk - TriplyDB

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

http://www.wikidata.org/entity/Q33161027

about

New treatment option for ovarian cancer: PARP inhibitors Trial watch - inhibiting PARP enzymes for anticancer therapy Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Olaparib in the management of ovarian cancer PARP inhibitors in the management of breast cancer: current data and future prospects Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate New perspectives on targeted therapy in ovarian cancer PARP inhibitor treatment in ovarian and breast cancer Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Development of synthetic lethality anticancer therapeutics.Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.Nivolumab and Olaparib.A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.Olaparib, PARP1 inhibitor in ovarian cancer.Olaparib: a promising PARP inhibitor in ovarian cancer therapy.Predictive biomarkers for cancer therapy with PARP inhibitors.Appraising iniparib, the PARP inhibitor that never was--what must we learn?Management options in locally advanced pancreatic cancer.Olaparib: first global approval.Safety evaluation of olaparib for treating ovarian cancer.Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.

P2860

Q26745614-4200F060-CA37-4ECC-BA14-13369F3763D6 Q26745673-820FD751-55D2-4188-8806-971E7B5DC277 Q26783551-BF6AD843-4246-4140-8D37-C7EB31ED6B63 Q26797166-73520253-4AA4-4655-B300-AAF4531195D3 Q26798352-CA42AB90-677F-412C-9CBF-53C87874E2FA Q27021794-55DA59A3-1237-487B-9BC4-D5C750E0603E Q28082524-6F1CBB00-A242-408D-97E9-2AB7C61155A7 Q28741688-4A85111A-7639-403D-8BC0-A7846E63ED7C Q33415400-6D4C936A-46C8-4CC9-A2B6-A58DBAFEA1E8 Q33416440-160048B9-F712-4F35-9169-C7B838BB9BC9 Q33422932-89D4700D-03A7-49B7-97E7-70A066E2571B Q33429434-4BAC8502-2B1E-44C2-B373-5E3C5C98C0DF Q33431474-7DDDD946-89B2-419F-B789-BC5CC3025CC0 Q33439527-BD2A3971-BF99-4CD3-80DF-84F4829A2A1C Q33617922-602E1528-6654-42B6-BF0C-5A2C459727AD Q33709593-0B1059EF-A45D-4F1C-B47C-23E443A5EA7D Q33874466-6F1A1EC8-BBEE-46FC-9CA3-A8BA227814C0 Q34380368-4350BEAF-6910-4BA6-9776-742FC0350A3B Q34982593-20AA2B47-ED7A-44B8-887C-661091160273 Q35909678-9820340F-36CA-4236-9B52-19A3714FEB50 Q36052253-5309DC35-354B-4906-8713-D36E13359A30 Q36432567-591CEA0E-4BCC-4E19-BE28-AE8C8309E2CB Q36490203-CAD28668-B12F-49F9-8DFD-88F3D8AFD3B8 Q36853236-CA5B5F01-B390-415E-946C-9FF0DF04637B Q37018223-2BDA767E-4384-4354-926C-FA1A2307FBB6 Q37169959-DAF58F02-171F-4995-B0FE-C700A59C5D42 Q37607283-C444238F-683C-4227-8785-FC9634DACEB5 Q37691181-7C9C944E-E7BD-443D-8CA6-4BAE4D9A8EB2 Q37697400-E93AAE49-7C9E-4410-91E2-156EC516CF07 Q38025738-627F33AA-B16C-4CF9-B043-1CCAF2685C39 Q38101861-800751F7-B465-41DD-8410-1B34B5A78DC3 Q38137764-3BF31495-4EB4-4642-9E9F-22832257750C Q38152942-C61DE9B7-13A3-4D2E-8733-23CC0EC4553C Q38205127-F8701189-B3CC-409A-A11F-9288878A5B64 Q38330356-02714EC6-6E36-438C-AF84-0A75BF83E20E Q38519719-00882A45-2A4B-40AB-B1BF-1201827AF063 Q38726394-ABEEAD20-336B-4055-9297-62B64333AEFA Q38747272-1C59A2E8-A333-4379-9304-FDDB8C943B45 Q38773634-BE495F82-6D7D-4B69-A7D3-F5C6442DDF1A Q38780396-66B40770-0A9B-4EBB-8B7A-4776D4499EA8

P2860

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

http://www.wikidata.org/entity/Q33161027

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A phase I combination study of ...... e in adults with solid tumors.

@ast

A phase I combination study of ...... e in adults with solid tumors.

@en

type

label

A phase I combination study of ...... e in adults with solid tumors.

@ast

A phase I combination study of ...... e in adults with solid tumors.

@en

prefLabel

A phase I combination study of ...... e in adults with solid tumors.

@ast

A phase I combination study of ...... e in adults with solid tumors.

@en

P1433

Q33161027-476C4C84-8D91-461B-BEE9-0EA99BF13213

P1476

Q33161027-5D6432D7-929B-476D-9223-66D7A7C7BD27

P2093

Q33161027-372E7ECE-4683-4A39-BDFA-E92C92B9F294

Q33161027-387250CA-55FD-41D5-8431-86C5473BB0A9

Q33161027-53E718FA-49C5-4CB0-91FB-2CE17EE976E0

Q33161027-599DB1F2-EAF3-4F30-8998-072F98C1165E

Q33161027-76038AA0-D623-4883-85FC-527031A7B128

Q33161027-95BA6775-5B11-4C9E-8D51-E4E99A80ACF8

Q33161027-ADD82DDC-4A40-4FAC-9A69-B7C4AEB61233

Q33161027-CF2D8B61-9D7C-4F6D-8609-EEF1D7C863BD

Q33161027-E0220663-0720-4A6B-B470-598A4535CF20

Q33161027-F45E5BCD-DA0E-4060-B1BE-577CE58A7D16

P304

Q33161027-B5CBFC47-441B-41A9-BA07-99E0CB1E793A

P31

Q33161027-29A30E18-5C95-4D7F-AE82-12BF910F2A78

P356

Q33161027-B679EF05-4F70-4CBF-8046-2A4D5B216D8B

P407

Q33161027-6DA7941C-49D0-4155-9115-0C3076D1FC0E

P433

Q33161027-4217DFA6-51B6-4191-806A-8BFD25B77A76

P478

Q33161027-B0840D00-3571-4A2E-809F-378993E9F75F

P50

Q33161027-21F69F81-AF9B-45DC-AFA0-84889B1CFFC3

Q33161027-4857CB6A-1643-42C2-A022-502EC663324C

Q33161027-CD56DD63-DFA7-49FF-A448-3707DD4FA61B

P577

Q33161027-F2D1129E-2218-44FF-A13C-869DAADC9526

P698

Q33161027-E6F4A208-F8BE-4B89-90D8-6C09DE51A19D

P932

Q33161027-807C4838-7012-44B6-8D06-7E64899ED42D

P356

1078-0432.CCR-11-2425

P1433

Clinical Cancer Research

P1476

A phase I combination study of ...... ne in adults with solid tumors

@en

P2093

Arun Rajan

http://www.w3.org/2001/XMLSchema#string

Corey A Carter

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Mary Ann Yancey

http://www.w3.org/2001/XMLSchema#string

Ronan J Kelly

http://www.w3.org/2001/XMLSchema#string

Shawn Spencer

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

Sukyung Woo

http://www.w3.org/2001/XMLSchema#string

William Douglas Figg

http://www.w3.org/2001/XMLSchema#string

P304

2344-2351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-2425

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

Baskar Mannargudi

P577

2012-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22371451

http://www.w3.org/2001/XMLSchema#string

P932

6368967

http://www.w3.org/2001/XMLSchema#string